Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report

Front Pharmacol. 2023 Jul 26:14:1256801. doi: 10.3389/fphar.2023.1256801. eCollection 2023.

Authors

Ningning Yan¹, Siyuan Huang¹, Linlin Li¹, Qianqian Guo¹, Di Geng¹, Huixian Zhang¹, Sanxing Guo¹, Xingya Li¹

Affiliation

¹ Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Abstract

[This corrects the article DOI: 10.3389/fphar.2022.898623.].

Keywords: NSCLC; ROS1; chemo-immunotherapy; immune checkpoint inhibitor; lung adenocarcinoma.

Copyright © 2023 Yan, Huang, Li, Guo, Geng, Zhang, Guo and Li.

Publication types

Published Erratum